Thursday, 29th August The Annual Scientific Meeting of the Australian Diabetes Society and the Australian Diabetes Educators Association 2013

Patient and HCP attitudes and behaviours towards insulin therapy in Australia (GAPP2), and latest news on Novo Nordisk injectable therapies
An international cross-sectional survey (GAPP2), with a cohort in Australia, was conducted to increase the understanding of basal insulin-taking with an aim to investigate the frequency and impact of basal insulin dosing irregularities and hypoglycaemia in type 2 diabetes. The survey was conducted with both patients and physicians, and thus the difference in perceptions between the two groups was explored. The survey found a proportion of patients dosed their basal insulin irregularly which may warrant more frequent discussion with prescribers to address the behaviours and reasons behind this.

Novo Nordisk is constantly exploring opportunities to make their products more widely available to a larger number of patient groups. An update to the audience will be provided on the latest developments of Novo Nordisk’s injectable portfolio.

Diabetes, high risk sub-groups and the implications of hypoglycaemia
This session will increase awareness of diabetes high risk sub-groups, such as the elderly and those with renal impairment. The implications of hyperglycaemia and hypoglycaemia within these groups will be discussed and management options will be reviewed. As a result of attending this session attendees will enhance their skills in avoiding hypoglycaemia whilst still achieving good glycaemic control.

Confirmed speakers are:
Dr Ted Wu - Senior Staff Specialist in Endocrinology and Diabetes, Director of Health Professional Training, Royal Prince Alfred, Camperdown, NSW
Associate Professor Marg McGill AM - Manager, Diabetes Centre, Royal Prince Alfred Hospital, Camperdown, NSW

Addressing the preventable toll of chronic disease and premature death among people with a serious mental illness

Kevin Humphries is the NSW Minister for Mental Health, Minister for Healthy Lifestyles and Minister for Western NSW.The Minister will discuss work being undertaken at a national level, commenced by a recent national summit formed to discuss the physical health of people with a mental illness and the high rates of chronic and preventable disease.

The summit was held in response to increasing concerns within the community and also growing evidence which shows that one in five Australians experience a mental health difficulty in any given year and the physical health of people living with a mental health difficulty is worse than those in the general community on just about every measure. Of particular focus is that people with a severe mental illness live between 10-32 years less than the general population. People with illnesses such as bipolar disorder or schizophrenia have heart-related problems, diabetes and obesity at much higher rates than the rest of the community.

An overview of dapagliflozin (FORXIGA®): clinical trials and in-clinic experience

Dapagliflozin (Forxiga) is a sodium glucose co-transporter inhibitor (SGLT2i), a new class of oral type 2 diabetes medication which inhibits renal glucose reabsorption resulting in urinary glucose excretion . The action of dapagliflozin is independent of insulin and does not impair normal endogenous glucose production in response to hypoglycaemia1. In addition to improving glycaemic control, the urinary glucose excretion induced by dapagliflozin is associated with reduction in weight but also contributes to its adverse effect profile which includes genital infections, urinary tract infections and volume depletion1. Dapagliflozin was the first SGLT2i to be approved for use in the management of type 2 diabetes1. It has been registered in Australia as well as in Europe. The objective of this symposium is to provide attendees with a balanced overview of the dapagliflozin clinical trials program and to share the early in-clinic experience with dapagliflozin in Europe.

• The importance of the social, physical and policy environment in preventing and controlling diabetes and related NCDs - Ruth Colagiuri

GP CME Eligible Session

• Management of Insulin Resistance and Beta Cell Dysfunction Late in Diabetes - Philip Home
• Early Management of insulin resistance in Type 2 Diabetes - Donald J Chisholm
• Late-stage Type 2 diabetes: can we target our therapies?  - Anthony Russell

• Mechanisms of Lipid-Induced Insulin Resistance in Muscle - Greg Cooney
• Antioxidants can impair skeletal muscle insulin sensitivity - Tony Tiganis
• Dissecting insulin resistance using gene expression signatures - Ken Walder

• Nox4 as a novel target to treat diabetic nephropathy - Karin AM Jandeleit-Dahm
• Doxycycline treatment improves granulation tissue quality but not wound closure rate in diabetic animals. - Sarah E Aamidor
• Monocyte Expression of the Haemoglobin Scavenger Receptor CD163: Possible Role in the Development of Diabetes Complications - Danqing Min
• GLYOXALASE-1 INHIBITION LEADS TO DIABETIC KIDNEY DISEASE ASSOCIATED WITH PODOCYTE INSULIN RESISTANCE - Linda A Gallo
• The DNA Binding Capacity of RAGE and its Consequences in the Development of Diabetic Nephropathy - Brooke Harcourt
• Association between Neutrophil Associated Lipocalin-2 (NGAL) and MMP-9 activity: Possible role in poor wound healing in diabetes - Maryam Abdollahi

• Differences in survival among multiple ethnic groups of Type 2 Diabetes in Australia - Turki Alharbi
• Recent diagnosis of diabetes mellitus is associated with mortality in older men. - Bu B Yeap
• All-cause and cardiovascular disease mortality in community-based patients with type 1 diabetes: The Fremantle Diabetes Study - Timothy ME Davis
• Queensland’s diabetic foot hospitalisation and amputation reduction:  Reducing the state of our foot hospital problem?  - Peter A Lazzarini
• THE DIABETES CARE PROJECT: A CLUSTER RANDOMISED TRIAL OF CARE FACILITATION AND STRUCTURED CLINICAL QUALITY IMPROVEMENT IN GENERAL PRACTICE IN 3 AUSTRALIAN STATES: BASELINE CLINICAL INDICATORS - Robyn McDermott
• DIABETES OUTREACH CLINIC FOR THE HOMELESS: A MODEL FOR IMPROVED CARE AND OUTCOMES? - Alexander Viardot

Peter Colman

Modifying the Natural History of Type 1 Diabetes Across the Life Spectrum

GP CME Eligible Session

An exploration of e-health and available technology and its applicability in diabetes self management in the 21^st century.

• Does Dr Google, Dr iPhone and other forms of technology work in diabetes self management? - Natalie Wischer
• Social Media and Health Care: how healthcare professionals can – and should – join in - Renza Scibilia
• Can technology really help Chronic Disease Management? - George Margelis
• Protection of Health Information – Guidelines for Compliance - Peter Croll

• In vivo regulation of beta cell differentiation and function - Lori Sussel
• Lab made insulin producing beta cells: Almost there - Ed Stanley
• Robust differentiation of purified islet progenitors into functional beta-like cells for diabetes cell therapy - Fang-Xu Jiang

• Determinants of Insulin-Sensitive Obesity - Daniel LT Chen
• Retrospective study of Type 1 Diabetes in Indigenous Australians in the Top End, Northern Territory (NT) - Ni Ni Khin
• Maternal vitamin D level, glycaemic control and pregnancy outcomes: results from a multi-ethnic population of women with gestational diabetes mellitus in South-Western Sydney - Min Ling
• Time to steady state circulating insulin levels following insulin pump basal rate changes in type 1 diabetes - Sybil A McAuley
• Better Than International Average HbA1c Reductions in Australian Insulin Pump Services for Adults with Type-1 Diabetes - Daniel A Calandro
• Hypoglycaemia induced acceleration of gastric emptying is attenuated by exogenous GLP-1 in healthy subjects - Mark P Plummer

• Type 1 Diabetes Mellitus management in hospital: the person's experience - Rebecca Munt
• Hospital hypoglycaemia management - are we there yet? - Ziping (Helen) Huang
• An Audit of Hypoglycaemic Presentations to the Emergency Department - Kathleen M Steele
• WHEN YOU CAN’T SEE EVERYONE! TRIAGING INPATIENT DIABETES REFERRALS FOR DIETETIC CARE. - Ros Smith
• Optimising inpatient glycaemic control by auditing the influence of blood glucose testing and compliance with insulin therapy - Elizabeth O'Meara
• Quantitative Retrospective Audit of the Insulin Stabilisation Service for patients with Type 1 and Type 2 Diaabetes at    Dandenong Hospital, Monash Health. - Rena Chand
• Insulin safety – using evaluation to inform strategic quality improvement - Margaret M Loh
• EVALUATION OF A CONTINUOUS GLUCOSE MONITORING SYSTEM IN A COMMUNITY AND PRIMARY CARE SETTING - Rachel Miller

• Improving self-monitoring of blood glucose among adults with type 1 diabetes: an interim analysis of The Mobile^TM Study - Jane Overland
• Development and Implementation of a new School Management Plan for Children with type 1 diabetes using Intensive Insulin Therapy. - Megan A Paterson
• Insulin administration in Australian primary schools: Kindergarten – Year 2. - Anne Marks
• THE HUNTER ezyBICC © AND SPIN PROGRAMS: A NOVEL APPROACH TO INTENSIVE INSULIN THERAPY IN THE REAL WORLD - Helen Phelan
• Mental health of adults with type I diabetes - Casey L O'Brien
• A MINDFULNESS GROUP TO REDUCE EMOTIONAL DISTRESS IN TYPE 1 DIABETES – RESULTS OF A PILOT PROGRAM - Sarah Lam

• PPARα activation stimulates UPR upstream pathways and corrects insulin resistance in high-fat fed mice in the presence of hepatosteatosis - Stanley MH Chan
• Regulation of glucose homeostasis by reversible lysine acetylation of GAPDH - Simon T Bond
• Nitric Oxide is Required for Increases in Insulin Sensitivity following ex vivo Mouse Skeletal Muscle Contraction via a cGMP/PKG Independent Pathway - Mary Xinmei Zhang
• Characterisation of the Adiponectin Receptors: Dimerisation and Palmitoylation of AdipoR1 and AdipoR2 are Required for Efficient Cell-Surface Expression. - Jon Whitehead
• Physiological testing reveals impaired muscle function in obese mice - Joseph Power
• Obese adipose tissue promotes monocytosis via macrophage activation of the NLRP3-inflammasome and IL-1β - Andrew J Murphy

• ADEQUACY OF GLYCEMIC CONTROL IN DIABETIC DIALYSIS PATIENTS - A SINGLE CENTRE PROSPECTIVE OBSERVATIONAL STUDY USING CONTINUOUS GLUCOSE MONITORING. - TALIB ALJUMAILY
• “Change in all things is sweet”: the effects of antipsychotic switching on glycemic control and obesity in chronic schizophrenia. - Rosanne Arnoldy
• National in-hospital nutrition guidelines for people with diabetes. Process and outcomes from a National Diabetes Services Scheme / Australian Diabetes Society initiative. - Elizabeth Blanchard
• Telehealth Eye and Associated Medical Services Network [TEAMSnet] Study:  The Australian Implementation of the Comprehensive Diabetes Management Program [CDMP] - Sven-Erik Bursell
• Vitamin C deficiency and diabetic foot ulcers - Darshika J Christie-David
• A Curious Case of Insulin Resistance: Subcutaneous Insulin Resistance Syndrome - Darshika Christie-David
• Evaluation of the Roche cobas b 101 Point of Care instrument in the diagnosis of diabetic patients - Penelope J Cowley
• How the St Vincent's declaration can help mental health clinicians HeAL the physical burden of disease in severe mental illness - Katherine Samaras
• Peer-to-peer, multidisciplinary, process-focussed education increases GP confidence in using insulin therapy in type 2 diabetes (T2D)  - Gary Deed
• Increased placental FGF21 expression in gestational diabetes mellitus (GDM) - Marloes Dekker Nitert
• A Case Of Acute Painful Neuropathy Following Rapid Glycemic Control - Danijela Dravec
• Rates of distress and depression in people with diabetes in a regional general practice - Hanna E Grimson
• Monitoring the well-being of people with diabetes: how to translate guidelines into routine care? The NDSS National Development Program for Mental Health and Diabetes - Jennifer Halliday
• Visceral fat accumulation and metabolic risk factors of westernized overweight young males of Asian and European descent  - Mehrdad Heydari
• Similar socio-economic and educational status of adults with Type 1 Diabetes using insulin pumps and multiple daily insulin injections - Alicia J Jenkins
• Genetic susceptibility to type 2 diabetes influences the impact of obesity on heart rate variability     - Arthur B Jenkins
• Demystifying Type 2 Diabetes for GP registrars - Mark F Kennedy
• An Integrated Model for Diabetes Care in Socio-Economically Disadvantaged Regional Victoria.A partnership between the public and private sector. - Mark F Kennedy
• GLYCAEMIC PROFILE & ADVERSE OUTCOMES IN PATIENTS RECEIVING ENTERAL NUTRITION - Mani Manoharan
• Patients and prescribers in type 2 diabetes reported on attitudes and behaviours towards irregular basal insulin dosing in Australia - Margaret McGill
• A rare case of Fulminant type 1B Diabetes - Mohammad Mir
• Fremantle Diabetes Study: Longitudinal Apathy - Melinda Nelson
• Glucose and insulin infusion usage outcomes before and after institution of peri-operative glucose management guidelines in cardiothoracic patients. - J Y K Ng
• INTERNATIONAL DIABETES FEDERATION LIFE FOR A CHILD PROGRAM - Graham D Ogle
• ONCE-DAILY LIXISENATIDE AS ADD-ON TO BASAL INSULIN ± OADS IN PATIENTS WITH TYPE 2 DIABETES SELECTIVELY REDUCES POSTPRANDIAL HYPERGLYCEMIC DAYTIME EXPOSURE - David O'Neal
• AUSTRALASIAN DIABETES DATA NETWORK (ADDN): COLLABORATION FOR FUTURE RESEARCH - Helen Phelan
• Changing from a glargine-based insulin regimen to biphasic insulin aspart 30 in people with type 2 diabetes - Alana Philips
• Efficacy, safety and tolerability in type 1 diabetes of insulin aspart administered by InsuJet^TM compared to subcutaneous injection. - Anne T Reutens
• Keeping the Body in Mind: Early detection and prevention of diabetes in youth with psychosis - Simon Rosenbaum
• Acute autoimmune autonomic neuropathy in a type 1 diabetic - Manodhi Saranapala
• An Audit -The Current State of diabetes care at a major diabetes clinic in Sri Lanka. - Manodhi Saranapala
• A RARE CASE OF MAURIAC SYNDROME - Ali Sharafi
• What is the difference between adult patients with and without Cystic Fibrosis Related Diabetes in Tasmania? - Anne Sillars
• A Bitter-Sweet Lesson - Lisa Simmons
• Experiences from a multidisciplinary high risk foot clinic: a 6 month descriptive analysis - Himali Suwandarathne
• Case series: the effect of bariatric surgery on glycaemic control in patients with type 1 diabetes mellitus - Alice Tang
• The incretin effect is reduced or may be not altered in patients with chronic kidney disease - Jessie Teng
• Poor adherence to treatment guidelines of diabetic ketoacidosis leads to increased incidence of hypokalemia - Geetha Theverkalam
• An Audit on Hypoglycaemia - Aye Thin
• Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide-1 receptor on gastric emptying, glycaemia and insulinaemia - Mahesh M Umapathysivam
• Effectiveness and safety of vildagliptin compared with other oral antidiabetic drugs in patients with type 2 diabetes: results from EDGE, a large worldwide observational study. - Chad Woodcock

GP CME Eligible Session

• Developing and Maintaining Diabetes Services across Australia in the New Millennium - Helena Teede

• Getting creative: designing and implementing interactive diabetes education - Melinda Maryniuk

Delegates involved in the poster discussion are required to stand by their poster on Thursday 29th August from 2:00 PM – 2:30 PM. Presentations will be in 5 minute slots – 3 minutes to summarise research and 2 minutes to answer any questions.

Complications Chairperson - Elif I Ekinci

Diabetic Foot Chairperson - Pete Lazzarini

Type 1/Young DM Chairperson - Maria Craig

Glycaemia/Validity Chairperson - Gregory Fulcher

Trials Chairperson - Neale Cohen

Treatment/Prevention Chairperson - Stephen Stranks

• Screening for cirrhosis secondary to Non-alcoholic fatty liver disease (NAFLD) in a diabetes centre population using NAFLD Fibrosis Score (NFS): an externally-validated, simple, biomarker panel - Kathryn H Williams
• Long-term Intraindividual Variability in Albumin Excretion Rate in Patients with Type II Diabetes - Amanda Leong
• Hypoglycaemia and QT Prolongation: Detection by Simultaneous Holter and Continuous Glucose Monitoring - Angela Lee
• Relationship between 24h urinary sodium-to-potassium ratio with blood pressure and renin angiotensin aldosterone activity in people with diabetes - Renata Libianto
• Gender differences in cardiovascular risk factors and mortality in type 2 diabetes: The Fremantle Diabetes Study - Jocelyn Drinkwater
• "People with diabetes admitted for acute heart failure have prolonged hospital stay and under-recognised diastolic dysfunction" - Avinash Suryawanshi
• Effects of hospital acquired conditions on length of stay for diabetic patients. - Jayde E Cromarty
• Queensland’s foot ulcer database:  Monitoring the characteristics and outcomes of Queensland’s foot ulcers - Peter A Lazzarini
• Diabetes-related foot complications as a risk factor for osteoporosis - Qian Sun
• Introduction of an Interdisciplinary Diabetes Foot Service and the effect on Inpatient Length of Stay. - Michaela Barron
• The economic impact of peripheral arterial disease on lower extremity intervention in patients with and without diabetes mellitus. - Matthew Malone
• Rates of admission for diabetic foot ulceration, and amputation rates, 2002-2011, in the absence of a diabetes foot team - Duncan Topliss
• A meta-analysis of FDG PET/CT versus MRI in diagnosing diabetic foot osteomyelitis - Kevin Lee
• Diabetes health-service delivery: The experiences of young adults with Type 1 diabetes. - Janice Wiley
• Diabetes education: the experiences of young adults with Type 1 diabetes - Janice Wiley
• Alcohol and hypoglycaemia in type 1 diabetes - Sally Vindedzis
• Documenting Insulin Non-adherence in Young Adults with Type 1 Diabetes - Melanie Burkhardt
• The blood glucose response to moderate-intensity exercise is reproducible in individuals with type 1 diabetes on basal subcutaneous insulin infusion - Timothy W Jones
• A Prospective Assessment of Time Spent by Healthcare Professionals in Managing Diabetes Patients on Insulin Pumps in Australia - David O'Neal
• Application of a MODY calculator in diabetic Australians: The Fremantle Diabetes Study Phase II - Ashley E Makepeace
• The Effect of Specialist Referral on HbA1c: Data from the Australian S4S-DINGO – Diabetes Informatics Group - Teresa Lam
• Saxagliptin as add-on to metformin + sulfonylurea: Outcomes stratified by baseline A1C and patient characteristics - Robert G Moses
• Statin therapy and glycaemia in community-based patients with type 2 diabetes: The Fremantle Diabetes Study - Michelle England
• Investigating clinical inertia in the management of patients with type 2 diabetes mellitus in St Vincent’s Hospital Melbourne - Alice Hong
• Pre analytical glucose loss secondary to glycolysis in the first hour after venous sampling   - Huan Chan
• Ultrasonographic assessment of carotid bruits detected by an electronic stethoscope in community-based patients with type 2 diabetes: The Fremantle Diabetes Study Phase II - Arthur Knapp
• META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF LIXISENATIDE AS ADD-ON TO BASAL INSULIN ± OADs IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - David O'Neal
• Response to dapagliflozin by baseline HbA1c in head-to-head comparisons - Shamik J Parikh
• Combined HbA1c and weight reduction is achieved more frequently with add-on dapagliflozin than add-on glipizide in patients with type 2 diabetes inadequately controlled on metformin - Shamik J Parikh
• Effectiveness and safety of starting insulin aspart premix therapy from different oral agents in routine clinical practice - John Miller
• Patients are more likely to reach A1c target at any given time during 26 weeks' treatment with liraglutide compared with both sitagliptin and exenatide - Mirella Daja
• Safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control - Stefan Orange
• Once daily liraglutide (1.2mg) vs twice daily exenatide (10ug) in the treatment of type 2 diabetes patients: a meta-analysis. - Mirella Daja
• Is Bariatric Surgery Being discussed as a Treatment option in appropriate patients with Type 2 Diabetes Mellitus? - Monika Fazekas
• Exenatide Therapy In An Indigenous Population with Type 2 Diabetes Aids in Substantial Weight Loss Even When The Glycaemic Response Fails: A Clinical Service Audit - A Traeger
• Metabolic outcomes in patients attending a Clozapine clinic - Christopher Muir
• High Quality Diet Associated with a Lower Risk of Type 2 Diabetes - Amani Alhazmi
• Total carbohydrate intake does not predict type2 diabetes risk in mid-age women from the Australian Longitudinal Study on Women's Health - Amani Alhazmi

• WHO Monitoring Framework for Non-Communicable Diseases - Ruth Colagiuri

• Type 1 Diabetes from the human perspective - Olle Korsgren

GP CME Eligible Session

The two societies bring out their best for an hour of skillful debating that will challenge your current ideas and move you to consider different points of view.

Moderator: Timothy Davis

Affirmative: Trisha O’Moore-Sullivan and Cheryl Steel

Negative: Wah Cheung and Glynis Dent

GP CME Eligible Session

• The Fremantle Diabetes Study: The first 20 years  - Timothy Davis
• The epidemiology of childhood diabetes  - Maria Craig
• AusDiab - Jonathan Shaw

• Glucotoxicity specifically impairs second-phase insulin secretion in an obese transgenic rat model - Christos N Joannides
• Alterations in the protein and lipid secretory profile of steatotic hepatocytes promote insulin resistance in cultured muscle cells - Ruth CR Meex
• The role of FXR in maternal obesity related renal injury in mother and offspring - Sarah J Glastras
• Intra-islet inflammation in Type-2 Diabetes: Evidence that the E3 ligase TRAF2 is a key protective factor for pancreatic beta cells - Elisabeth K Malle
• Fenofibrate protects against adverse effects of the in-vitro diabetes metabolic environment on telomeres: role of Trf gene regulation - Surya Sutanto
• Re-evaluating the mechanisms of high fat diet-induced defects in hepatic and whole body glucose metabolism: insights from dynamic ¹³C and ²H stable isotope metabolomic profiling - Greg M Kowalski
• Therapeutic blockade of IL-6 trans-signaling rescues adipose tissue inflammation, but not insulin resistance, in high fat fed mice. - Michael Kraakman
• Loss of the pro-apoptotic molecule Bim improves beta-cell function and glucose homeostasis in mouse models of type 2 diabetes - Jibran A Wali

• METHOD VARIABILITY IN HbA1c DETERMINATIONS. RESULTS FROM RCPAQAP SURVEYS - Paul Williams
• ASSOCIATION BETWEEN POORLY CONTROLLED PRE-OPERATIVE DIABETES MELLITUS AND POST-OPERATIVE COMPLICATIONS - Arpudaswamy Kumar
• A randomised controlled trial investigating the effects of a low glycaemic index diet on pregnancy outcomes in women at high risk of gestational diabetes mellitus - Tania Markovic
• GDM among women who are overweight and obese: the effect of BMI category. - Kate E Martin
• Weight Loss is Good Medicine: a Randomised Trial of Gastric Band Surgery in Overweight but not Obese People with Type 2 Diabetes - John Wentworth
• Adipose tissue regulation of cell-mediated inflammation and 12-month outcomes after bariatric surgery in obesity and type 2 diabetes. - Katherine Samaras
• Weight loss following laparoscopic adjustable gastric banding prevents progression from impaired fasting glucose to diabetes - John Wentworth
• Increasing dietary protein improves 24-hour and post-prandial glucose concentrations - Rosemary M Hall

Only ADS Members are able to attend the Annual General Meeting